Abstract
The European Directive 98/79/EC on in vitro diagnostic medical devices (IVD) regulates the marketing and post market surveillance of IVD in the European Economic Area. In cases of incidents and field corrective actions, the manufacturers have to inform the responsible Competent Authorities (CA). In Germany, the Federal Institute for Drugs and Medical Devices (BfArM) is the responsible CA for most IVD. In this study all notifications regarding IVD for therapeutic drug monitoring (TDM) between begin 1999 until end of 2010 were analysed. A total of 2,851 notifications were received, of which 65 were related to IVD for TDM included in this study (54 tests vs. 11 analysers). Reports were received from manufacturers (58), CAs (5 cases) and users (2 cases). Most frequently IVD used for TDM of toxicologically relevant substances, antibiotics, antiepileptics and immunosuppressives were affected. Investigations of the manufacturers were able to identify the underlying root causes of product failures in 50 cases (76.9%), 40 (74.1%) of which were tests and 10 (90.9%) analysers. In 11 cases (16.9%, all tests), the root cause remained unclear and in 4 cases (6.2%, 3 tests, 1 analyser) a product failure was excluded. Product failures in tests were most commonly material defects (12 cases), interferences (7 cases) and manufacturing errors (7 cases), whereas in the analyser group software errors (5 cases) were most common. Corrective actions were performed in 56 cases (86.2%); 46 (85.2%) in tests, and 10 (90.9%) in analysers. In the group of tests these were predominantly (multiple entries) customer information (46 cases, mandatory in case of a recall), recall (29 cases), modifications in production or quality management (29 cases) and modifications of the instructions for use (9 cases). However, in the analyser group corrective actions were typically customer information (10 cases), recall (5 cases) and software-update (4 cases). The obtained data demonstrate that there are differences in the type of product failures between analysers and tests, which are followed by different corrective actions depending on the root causes of product failure accordingly. The results and the experience since 1999 suggest that the system for post marketing surveillance of IVD is an established tool to enhance product safety even though further optimisation is possible.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on In Vitro Diagnostic Medical Devices. Official Journal L 331:1–37 / http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31998L0079:EN:HTML
Guidelines on a Medical Devices Vigilance System. (2007). (MEDDEV2.12-1rev).5/Internet: http://ec.europa.eu/consumers/sectors/medical-devices/documents/guidelines/
Halbauer, J., Siekmeier, R., & Funk, M. (2009). Die Sicherheit von Hochrisiko-in-vitro-Diagnostika. Internationale und nationale Maßnahmen. Bundesgesundheitsblatt Gesundheitsforschung. Gesundheitsschutz, 52, 610–618.
Medizinproduktegesetz in der Fassung der Bekanntmachung vom 7. August 2002 (BGBl. I S. 3146), geändert durch Artikel 1 des Gesetzes vom 14. Juni 2007 (BGBl. I S. 1066), zuletzt geändert durch Artikel 6 des Gesetzes vom 29. Juli 2009 (BGBl. I S. 2326)/Internet: http://bundesrecht.juris.de/mpg/index.html
Siekmeier, R., & Lütz, J. (2007a). Experience with post-market surveillance of in-vitro diagnostic medical devices for lay use in Germany. Clinical Chemistry and Laboratory Medicine, 45, 396–401.
Siekmeier, R., & Lütz, J. (2007b). Safety of in-vitro-diagnostics for hematology and coagulation testing – Analysis of the reports to the German Competent Authority (BfArM). Transfusion Medicine and Hemotherapy, 34, 353–361.
Siekmeier, R., Halbauer, J., Mientus, W., & Wetzel, D. (2008). Safety of reagents for infection testing: results of the market surveillance by the Federal Institute for Drugs and Medicinal Devices until end 2006. J Physiol Pharmacol, 59(Suppl. 6), 629–643.
Siekmeier, R., Halbauer, J., Mientus, W., & Wetzel, D. (2009). Safety of laboratory analyzers for infection testing – Results of the market surveillance by the BfArM until end 2007. European Journal of Medical Research, 14(Suppl. IV), 216–226.
Siekmeier, R., Lisson, K., & Wetzel, D. (2010). Field safety notices related by manufacturers in cases of failure of products for infection testing: Analysis of cases reported to the BfArM between 2005 and 2007. European Journal of Medical Research, 15(Suppl. II), 175–183.
Spitzenberger, F., Edelhäuser, R., Funk, M., & Halbauer, J. (2007). Vigilance experience for high-risk IVDs in Europe. Regulatory Affairs Journal Devices, 15, 157–164.
Verordnung über die Erfassung, Bewertung und Abwehr von Risiken bei Medizinprodukten (Medizinprodukte-Sicherheitsplanverordnung – MPSV) vom 24. Juni 2002 (BGBl. I S. 2131), zuletzt geändert durch Artikel 3 des Gesetzes vom 29. Juli 2009 (BGBl. I S. 2326)/Internet: http://www.gesetze-im-internet.de/mpsv/index.html
Conflicts of interest: The authors declare no conflicts of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this paper
Cite this paper
Siekmeier, R., Wetzel, D. (2013). Market Surveillance of In Vitro Diagnostics by the BfArM Until End 2010: Safety of IVD for Therapeutic Drug Monitoring. In: Pokorski, M. (eds) Respiratory Regulation - Clinical Advances. Advances in Experimental Medicine and Biology, vol 755. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4546-9_48
Download citation
DOI: https://doi.org/10.1007/978-94-007-4546-9_48
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-4545-2
Online ISBN: 978-94-007-4546-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)